Autopsy report · NCT03386838

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

“Business objectives have changed.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Bristol-Myers Squibb

Sponsor type

Industry

Conditions

Head and Neck Cancer

Interventions

Nivolumab; BMS-986205; Cetuximab; Cisplatin; Carboplatin; Fluorouracil

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Entecavir Plus Adefovir in Lamivudine-Resistant Patients
  “Business Objectives Changed” (93% match in meaning)
• A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
  “Business objective has changed” (91% match in meaning)
• Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors
  “(Non-safety reason, business objectives have changed)” (72% match in meaning)
• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
  “Business strategy change” (71% match in meaning)
• A Prospective Study of the NUVANCE Facial Rejuvenation System for Mid-Face, Neck and Jowl Rejuvenation Procedures
  “Change in business priorities.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.